Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Cash from Financing Activities of -$538.8 million for Q1 2026, up 20.81% year-over-year from -$446.0 million in Q1 2025, and down 597.93% quarter-over-quarter from -$77.2 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$538.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 20.81% year-over-year to -$538.8 million; the TTM figure through Mar 2026 stood at -$2.1 billion (down 16.61% YoY), while the FY2025 annual figure was -$2.3 billion, down 51.27% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$538.8 million, down from -$77.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $47.7 million in Q2 2022, with the low at -$1.2 billion in Q3 2025.
- The 5-year median for Cash from Financing Activities is -$294.7 million (2023), against an average of -$289.7 million.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities surged 111.96% in 2022, then plunged 2172.83% in 2024.
- Vertex Pharmaceuticals' Cash from Financing Activities stood at $40.2 million in 2022, then plunged by 398.01% to -$119.8 million in 2023, then tumbled by 226.63% to -$391.3 million in 2024, then soared by 80.27% to -$77.2 million in 2025, then slumped by 597.93% to -$538.8 million in 2026.
- Business Quant data shows VRTX's Cash from Financing Activities at -$538.8 million in Q1 2026, -$77.2 million in Q4 2025, and -$1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -181.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -426.70 Mn |
| Jun 30, 2026 | -426.70 Mn |
| Mar 31, 2026 | -538.80 Mn |
| Mar 31, 2026 | -538.80 Mn |
| Dec 31, 2025 | -77.20 Mn |
| Dec 31, 2025 | -77.20 Mn |
| Sep 30, 2025 | -1.15 Bn |
| Sep 30, 2025 | -1.15 Bn |
| Jun 30, 2025 | -349.20 Mn |
| Jun 30, 2025 | -349.20 Mn |
| Mar 31, 2025 | -680.40 Mn |
| Mar 31, 2025 | -680.40 Mn |
| Dec 31, 2024 | -391.30 Mn |
| Dec 31, 2024 | -391.30 Mn |
| Sep 30, 2024 | -387.50 Mn |
| Sep 30, 2024 | -387.50 Mn |
| Jun 30, 2024 | -358.60 Mn |
| Jun 30, 2024 | -358.60 Mn |
| Mar 31, 2024 | -357.50 Mn |
| Mar 31, 2024 | -357.50 Mn |